查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1559715

酵素结合免疫吸附检测法(ELISA) 测试的全球市场

Enzyme-linked Immunosorbent Assay (Elisa) Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 163 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到2030年，全球酵素结合免疫吸附检测法（ELISA）测试市场预计将达到16亿美元

酵素结合免疫吸附检测法(Elisa) 检测的全球市场预计 2023 年为 9.621 亿美元，预计到 2030 年将达到 16 亿美元，2023-2030 年分析期间复合年增长率为 7.7%。三明治 ELISA 测试是本报告分析的细分市场之一，预计复合年增长率为 7.9%，到分析期结束时将达到 7.841 亿美元。在分析期间，间接 ELISA 测试领域的复合年增长率估计为 6.5%。

美国市场预估为2.647亿美元，中国预期复合年增长率为7.1%

预计 2023 年美国酵素结合免疫吸附检测法(ELISA) 检测市场规模将达 2.647 亿美元。中国作为世界第二大经济体，预计到 2030 年市场规模将达到 2.48 亿美元，2023-2030 年分析期间复合年增长率为 7.1%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 7.2% 和 6.1%。在欧洲，德国的复合年增长率预计约为 6.2%。

全球酵素结合免疫吸附检测法(ELISA) 测试市场 - 主要趋势与驱动因素总结

酵素结合免疫吸附检测法(ELISA) 检验将如何彻底改变诊断与研究？

酵素结合免疫吸附检测法(ELISA) 测试为检测和定量蛋白质、荷尔蒙、抗体和其他生物分子提供了灵敏且特异性的方法，正在彻底改变诊断和研究。 ELISA 检测广泛应用于临床实验室、药物研究和生物技术，用于诊断感染疾病、监测免疫反应以及检测与癌症、爱滋病毒和自体免疫疾病等各种健康状况相关的生物标记。 ELISA 可以准确测量特定抗原和抗体，是医疗保健提供者和研究人员的重要工具。此技术通用性强，可应用于疾病诊断、疫苗研发、药效检测、食品安全监测等。随着对准确、可靠和具有成本效益的诊断的需求不断增加，ELISA 检测在推进公共卫生、医学研究和治疗开发方面继续发挥关键作用，为及时有效的干预提供了基础。

有哪些技术创新可以提升 ELISA 检测的功能？

自动化、多重检测和照护现场(POC) 检测的创新大大提高了 ELISA 检测的功能。自动化透过实现高通量筛检、减少人为错误并提高分析速度，彻底改变了 ELISA 工作流程。自动化 ELISA 系统，包括机器人分配、自动盘式分析仪和整合软体，使实验室能够同时处理数百或数千个样本，从而提高效率并缩短获得诊断结果的时间。这些系统还标准化了程序，确保不同测试之间的结果一致，并减少体力劳动可能发生的变化。自动化在大规模临床诊断、药物研究和流行病学研究中尤其重要，其中快速检体处理对于及时决策至关重要。

多重分析是 ELISA 技术的另一项重大进步，能够测量一个样本中的多种分析物。传统 ELISA 测试通常一次测量一个目标，而多重 ELISA套件可以同时检测和量化多个生物标记。这项创新显着减少了分析血液和血清等复杂生物样本所需的时间和资源，并在单次检测中提供全面的资料。多重 ELISA 在需要测量多种细胞激素、荷尔蒙和疾病标记物以了解疾病机制和治疗效果的研究中特别有用。此功能在个人化医疗中也很有用，可以同时测量多个生物标记物，为每位患者提供量身定制的治疗。

即时 (POC) ELISA 检测是另一项突破，它允许在传统实验室之外进行 ELISA 检测，例如在诊所、偏远地区或家用。可携式ELISA 设备旨在通常在几分钟内提供现场快速诊断结果。这些系统在资源匮乏的环境和快速诊断和治疗至关重要的紧急情况下特别有用。针对 HIV、肝炎和 COVID-19 等疾病的 POC ELISA 检测的开发极大地扩大了诊断范围，并改善了服务不足人群的医疗保健服务。这些可携式系统通常具有简化的工作流程，可由非专家操作，从而扩大了 ELISA 技术的应用范围。

奈米技术也提高了 ELISA 测试的灵敏度。金奈米颗粒等奈米材料被纳入ELISA检验中，以放大讯号并提高检测极限，从而能够检测极低浓度的生物标记。这对于早期疾病检测尤其重要，识别低浓度的特异性抗原或抗体可以导致早期疗育并改善患者预后。灵敏度的提高正在突破 ELISA 检测的极限，并在分子层面上实现更准确的诊断和研究。

ELISA检测对疾病诊断和治疗有何影响？

ELISA 检测提供可靠、灵敏且易于使用的方法来检测血液、唾液、尿液和其他生物样本中与疾病相关的生物标记物，从而改善疾病诊断，并对治疗产生重大影响。 ELISA 的主要优点之一是能够检测与感染疾病相关的抗体、抗原和其他蛋白质，使其成为诊断 HIV、肝炎、莱姆病和马苏病等疾病的重要工具。例如，在 HIV 诊断中，ELISA 经常被用作初步筛检测试，以检测是否有针对该病毒的抗体。早期发现此类感染疾病对于开始治疗、预防疾病进展和减少传播至关重要。

在肿瘤学中，ELISA 测试广泛用于测量肿瘤标记，例如 PSA（前列腺特异性抗原）和 CA-125（癌症抗原 125），这些标记可用于诊断癌症和监测其进展。透过量化这些标誌物，临床医生可以评估肿瘤活动、评估治疗效果并检测復发。 ELISA 测试的高特异性使得即使在复杂的生物样本中也能准确测量这些标记物，为个人化治疗计划提供重要资讯。同样，在狼疮和类风湿性关节炎等自体免疫疾病中，ELISA 可用于检测特定自体抗体的存在，帮助临床医生更有效地诊断和管理这些疾病。

除了诊断之外，ELISA 测试在监测对疫苗和治疗的免疫反应方面也发挥着重要作用。例如，在疫苗研究中，ELISA 可以测量疫苗接种后抗体的产生，从而深入了解疫苗功效和保护持续时间。这对于 COVID-19 疫苗的开发尤其重要，其中 ELISA 测试用于评估临床试验中的免疫反应。 ELISA 也用于治疗药物监测，透过测量血液中的药物浓度，帮助临床医生确保为患者施用最佳剂量的生物製药或其他治疗药物。

ELISA 在确定治疗策略方面的作用超出了人类医疗保健的范围。在兽医学中，ELISA检测用于检测牛结核病和禽流感等动物疾病，有助于保护动物健康并防止人畜共通感染疾病传播给人类。此外，ELISA广泛应用于食品安全检测，以检测过敏原、病原体和污染物，确保食品符合安全标准且不含有害物质。

ELISA 测试提供准确、及时且经济高效的诊断，可显着改善患者照护、加强疾病管理并支持各种医疗和科学应用以取得更好的结果。

推动 ELISA 检测市场成长的趋势是什么？

推动 ELISA 检测市场成长的趋势包括感染疾病的传播、癌症早期检测需求的增加、个人化医疗的扩展以及自动化和多重技术的进步。 HIV、肝炎和最近的 COVID-19 等感染疾病的全球负担日益增加，是推动 ELISA 检测需求的最大因素之一。随着医疗保健系统致力于减少这些疾病的传播，ELISA 已成为大规模诊断筛检的重要工具，特别是在高流行地区。为了应对大流行的威胁，对快速、准确和方便的诊断测试的需求将进一步加速 ELISA 测试在临床和照护现场环境中的采用。

对癌症早期检测的需求不断增长也是推动 ELISA 市场的一个主要趋势。随着全球癌症发生率持续上升，人们越来越重视开发能够在治疗最有效的早期阶段检测癌症的诊断工具。 ELISA 可以测量肿瘤标记和其他癌症相关蛋白，已成为早期检测策略的重要组成部分，特别是在前列腺癌、卵巢和乳癌筛检计画中。 ELISA与液态切片和分子诊断等其他诊断技术的结合有望提供更全面、更准确的癌症检测解决方案，并加强其在肿瘤学领域的作用。

个人化医疗的成长也促进了 ELISA 检测市场的扩大。个人化医疗依赖生物标记的识别来为个别患者量身定制治疗方案，而 ELISA 是测量这些生物标记的重要工具。对于自体免疫疾病、心血管疾病、癌症等疾病，个人化治疗方案依赖ELISA提供的准确的生物标记资料。随着精准医学领域的发展，对支持生物标记发现、药物开发和个人化治疗监测的 ELISA 测试的需求预计将会增加。

自动化和多重技术的进步使 ELISA 测试更加高效和可扩展，进一步推动了成长。自动化 ELISA 系统可降低人事费用，最大限度地减少人为错误，并实现高通量测试，这对于大规模临床诊断和研究至关重要。多重 ELISA 可以在一次测定中测量多种生物标记物，简化您的工作流程并提供每个样本的更全面的资料。这些创新使 ELISA 对于希望提高检测能力同时保持准确性和一致性的实验室更具吸引力。

法规和行业标准也促进了 ELISA 市场的成长。随着美国食品药物管理局(FDA) 和欧洲药品管理局(EMA) 等监管机构对药物安全、疫苗功效和诊断准确性实施更严格的指导方针，ELISA 检测作为确保合规性的重要工具变得越来越重要。此外，专注于疾病控制和预防的全球卫生倡议的兴起，例如世界卫生组织 (WHO) 的感染疾病控制倡议，增加了对基于 ELISA 的可靠诊断的需求。

这些趋势凸显了 ELISA 检测在诊断、研究和个人化医疗中日益增长的重要性。随着技术进步不断提高 ELISA 测试的准确性、速度和可及性，由于日益复杂的医疗保健环境中对准确、可靠和扩充性的诊断解决方案的需求，市场不断增长，我们相信我们将实现可持续增长。

调查企业举例（共22家）

  • Abcam PLC
  • American Laboratory Products Company（ALPCO）
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP11837

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market to Reach US$1.6 Billion by 2030

The global market for Enzyme-linked Immunosorbent Assay (Elisa) Testing estimated at US$962.1 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Sandwich ELISA Testing, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$784.1 Million by the end of the analysis period. Growth in the Indirect ELISA Testing segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$264.7 Million While China is Forecast to Grow at 7.1% CAGR

The Enzyme-linked Immunosorbent Assay (Elisa) Testing market in the U.S. is estimated at US$264.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$248.0 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market - Key Trends and Drivers Summarized

How Is Enzyme-Linked Immunosorbent Assay (ELISA) Testing Revolutionizing Diagnostics and Research?

Enzyme-Linked Immunosorbent Assay (ELISA) testing is revolutionizing diagnostics and research by providing a highly sensitive and specific method for detecting and quantifying proteins, hormones, antibodies, and other biomolecules. Widely used in clinical laboratories, pharmaceutical research, and biotechnology, ELISA tests are essential for diagnosing infectious diseases, monitoring immune responses, and detecting biomarkers related to various health conditions, including cancer, HIV, and autoimmune disorders. The ability to measure specific antigens or antibodies with precision makes ELISA an indispensable tool for both healthcare providers and researchers. The technique’s versatility allows it to be applied in disease diagnostics, vaccine development, drug efficacy testing, and food safety monitoring. As the demand for accurate, reliable, and cost-effective diagnostic methods grows, ELISA testing continues to play a critical role in advancing public health, medical research, and therapeutic development, providing the foundation for timely and effective interventions.

What Innovations Are Enhancing the Functionality of ELISA Testing?

Innovations in automation, multiplexing, and point-of-care (POC) testing are significantly enhancing the functionality of ELISA tests. Automation has transformed ELISA workflows by allowing high-throughput screening, reducing human error, and increasing the speed of analysis. Automated ELISA systems, which include robotic pipetting, automated plate readers, and integrated software, enable laboratories to process hundreds or thousands of samples simultaneously, improving efficiency and reducing turnaround time for diagnostic results. These systems also standardize procedures, ensuring consistent results across different tests and reducing variability that can occur with manual processes. Automation is particularly important in large-scale clinical diagnostics, pharmaceutical research, and epidemiological studies where the rapid processing of samples is essential for timely decision-making.

Multiplexing, which allows multiple analytes to be measured in a single sample, is another major advancement in ELISA technology. Traditional ELISA tests typically measure one target at a time, but multiplex ELISA kits can detect and quantify several biomarkers simultaneously. This innovation significantly reduces the time and resources needed to analyze complex biological samples, such as blood or serum, providing comprehensive data in a single assay. Multiplex ELISA is particularly useful in research settings where multiple cytokines, hormones, or disease markers need to be measured to understand disease mechanisms or treatment efficacy. This capability is also beneficial in personalized medicine, where simultaneous measurement of multiple biomarkers helps tailor treatments to individual patients.

Point-of-care (POC) ELISA testing represents another breakthrough, making it possible to perform ELISA tests outside of traditional laboratories, such as in clinics, remote areas, or even at home. Portable ELISA devices are designed to provide rapid, on-site diagnostic results, often within minutes. These systems are particularly valuable in low-resource settings or during emergencies, where quick diagnosis and treatment are critical. The development of POC ELISA tests for diseases like HIV, hepatitis, and COVID-19 has greatly expanded access to diagnostics, improving healthcare delivery in underserved populations. These portable systems are often user-friendly, with simplified workflows that can be operated by non-specialists, broadening the reach of ELISA technology.

Nanotechnology is also enhancing the sensitivity of ELISA tests. Nanomaterials, such as gold nanoparticles, are being integrated into ELISA assays to amplify signals and improve detection limits, making it possible to detect extremely low concentrations of biomarkers. This is particularly important in early disease detection, where identifying low levels of a specific antigen or antibody can lead to earlier interventions and better patient outcomes. These advancements in sensitivity are helping to push the boundaries of ELISA testing, allowing for more accurate diagnosis and research at the molecular level.

How Does ELISA Testing Impact Disease Diagnosis and Treatment?

ELISA testing has a profound impact on disease diagnosis and treatment by providing a reliable, sensitive, and accessible method for detecting disease-related biomarkers in blood, saliva, urine, or other biological samples. One of the primary benefits of ELISA is its ability to detect antibodies, antigens, and other proteins associated with infectious diseases, making it a crucial tool for diagnosing conditions like HIV, hepatitis, Lyme disease, and COVID-19. In HIV diagnostics, for example, ELISA is often used as an initial screening test to detect the presence of antibodies against the virus. Early detection of such infections is critical for initiating treatment, preventing disease progression, and reducing transmission.

In oncology, ELISA tests are widely used to measure tumor markers, such as PSA (prostate-specific antigen) or CA-125 (cancer antigen 125), which help in diagnosing and monitoring cancer progression. By quantifying these markers, clinicians can assess tumor activity, evaluate the effectiveness of treatments, and detect recurrences. The high specificity of ELISA tests ensures that these markers can be accurately measured even in complex biological samples, providing essential information for personalized treatment planning. Similarly, in autoimmune diseases like lupus or rheumatoid arthritis, ELISA is used to detect the presence of specific autoantibodies, helping clinicians diagnose and manage these conditions more effectively.

In addition to diagnostics, ELISA testing plays a critical role in monitoring the immune response to vaccines and therapies. For example, in vaccine research, ELISA can measure the production of antibodies in response to vaccination, providing insights into vaccine efficacy and duration of protection. This has been particularly important during the development of COVID-19 vaccines, where ELISA tests were used to assess immune responses in clinical trials. ELISA is also used in therapeutic drug monitoring, where it helps clinicians ensure that patients are receiving optimal doses of biologics or other therapies by measuring drug levels in the blood.

ELISA’s role in guiding treatment decisions extends beyond human healthcare. In veterinary medicine, ELISA tests are used to detect diseases in animals, such as bovine tuberculosis or avian influenza, helping to protect animal health and prevent the spread of zoonotic diseases to humans. Additionally, ELISA is widely employed in food safety testing to detect allergens, pathogens, and contaminants, ensuring that food products meet safety standards and are free from harmful substances.

By providing accurate, timely, and cost-effective diagnostics, ELISA testing significantly improves patient care, enhances disease management, and supports better outcomes across a range of medical and scientific applications.

What Trends Are Driving Growth in the ELISA Testing Market?

Several trends are driving growth in the ELISA testing market, including the increasing prevalence of infectious diseases, the rising demand for early cancer detection, the growth of personalized medicine, and advancements in automation and multiplexing technologies. The growing global burden of infectious diseases, such as HIV, hepatitis, and more recently, COVID-19, is one of the most significant factors fueling demand for ELISA tests. As healthcare systems focus on controlling the spread of these diseases, ELISA is a key tool for large-scale diagnostic screening, particularly in high-prevalence regions. The need for rapid, accurate, and accessible diagnostic tests in response to pandemic threats has further accelerated the adoption of ELISA testing in both clinical and point-of-care settings.

The rising demand for early cancer detection is another major trend driving the ELISA market. As cancer rates continue to increase globally, there is a growing emphasis on developing diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. ELISA’s ability to measure tumor markers and other cancer-related proteins makes it an essential part of early detection strategies, particularly in screening programs for prostate, ovarian, and breast cancer. The integration of ELISA with other diagnostic technologies, such as liquid biopsies and molecular diagnostics, is expected to enhance its role in oncology, offering more comprehensive and accurate cancer detection solutions.

The growth of personalized medicine is also contributing to the expansion of the ELISA testing market. Personalized medicine relies on the identification of biomarkers to tailor treatments to individual patients, and ELISA is a key tool for measuring these biomarkers. In conditions like autoimmune diseases, cardiovascular disorders, and cancers, personalized treatment plans depend on precise biomarker data, which ELISA provides. As the field of precision medicine grows, demand for ELISA testing to support biomarker discovery, drug development, and personalized treatment monitoring is expected to rise.

Advancements in automation and multiplexing technologies are further driving growth by making ELISA testing more efficient and scalable. Automated ELISA systems are reducing labor costs, minimizing human error, and enabling high-throughput testing, which is crucial for large-scale clinical diagnostics and research. Multiplex ELISA, which allows multiple biomarkers to be measured in a single assay, is streamlining workflows and providing more comprehensive data from each sample. These innovations are making ELISA more appealing for laboratories seeking to increase testing capacity while maintaining accuracy and consistency.

Regulatory and industry standards are also contributing to the growth of the ELISA market. As regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), enforce stricter guidelines on drug safety, vaccine efficacy, and diagnostic accuracy, ELISA testing is becoming increasingly important for ensuring compliance. Additionally, the rise of global health initiatives focused on disease control and prevention, such as the World Health Organization’s (WHO) efforts to combat infectious diseases, is increasing the demand for reliable ELISA-based diagnostics.

These trends highlight the growing importance of ELISA testing in diagnostics, research, and personalized medicine. As technological advancements continue to improve the accuracy, speed, and accessibility of ELISA tests, the market is poised for sustained growth, driven by the need for precise, reliable, and scalable diagnostic solutions in an increasingly complex healthcare landscape.

Select Competitors (Total 22 Featured) -

  • Abcam PLC
  • American Laboratory Products Company (ALPCO)
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Bolstering Demand for ELISA Testing
    • Increasing Use of ELISA in Drug Monitoring and Pharmaceutical Applications
    • Impact of Global Health Initiatives on Infectious Disease Detection via ELISA
    • Integration of Automation in ELISA Procedures to Increase Throughput
    • Market Trends Toward Multiplex ELISA for Simultaneous Detection of Multiple Targets
    • Rising Importance of Food Safety Testing Fueling ELISA Adoption
    • Advancements in Biomarker Discovery Driving ELISA Usage in Clinical Trials
    • Consumer Demand for Rapid Diagnostic Tests Influencing ELISA Kit Developments
    • Expansion of Point-of-Care Testing Incorporating ELISA Technologies
    • Future Directions: Integration of AI for Enhanced Data Analysis in ELISA Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sandwich ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Indirect ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Multiple & Portable ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION